Testoderm Articles
Atrix submits NDA to FDA for Leuprogel three-month product
28 September 2001
Amgen pulls out of Plenaxis alliance
19 September 2001
Solvay gets rights to hormone product
7 September 2001
Paladin acquires hyperthyroid drug from Merck Frosst
3 September 2001
Cellegy and PanGeo sign Tostrex deal
24 August 2001
BioSante sublicenses hormone product to Solvay
22 August 2001
Positive results for Watson's Oxytrol
16 August 2001
Novartis files Estradot in the EU
7 August 2001
FDA raises issues on Schering AG's HRT NDA
5 July 2001
US FDA rejects Amgen/Praecis cancer drug Plenaxis
14 June 2001
Antares/BioSante start Ph II trial of LibiGel
8 June 2001
NexMed's Alprox effective for ED in Phase II
7 June 2001
Unimed, TAP to copromote AndroGel
7 June 2001
Positive Ph III data for Praecis' abarelix
6 June 2001
Watson files NDA for oxybutynin patch
1 May 2001
J&J beats forecasts with 14% EPS rise
18 April 2001
Low-dose Climara cleared in USA
11 April 2001
Galen's IVR product approved in the UK
10 April 2001
Noven needs new study for ADHD patch
2 April 2001
Alza to set up manufacturing facility in Ireland
27 February 2001
Belgium's Solvay places emphasis on growing pharmaceuticals further
12 February 2001
J&J sales up despite Propulsid problem
24 January 2001
Elan Corp establishes JV with Generex
5 January 2001
J&J files NDA for Ortho Evra in USA
28 December 2000
US NDA for Praecis' abarelix depot
14 December 2000
Chinese approval for NexMed's Alprox-TD?
13 December 2000
Atrix plans to file for prostate cancer drug
7 December 2000
Novartis and Noven sign EstradotT deal
9 November 2000
Schering licenses Population Council's MENT
2 November 2000
Johnson & Johnson earnings climb 14%
18 October 2000
Argentina's Ethical pact with Cadila
26 September 2000
Noven's Vivelle cleared for osteoporosis prevention
23 August 2000
J&J beats forecasts with 2nd qtr earnings
20 July 2000
Ph III data with Amgen/Praecis' cancer drug
25 May 2000
Orion Pharma licenses Nestorone
26 April 2000
Bayer to market Alza's new Viadur implant in the USA
6 April 2000
Alza's Viadur approved for prostate cancer
8 March 2000
SkyePharma outlines mission to become major player in drug delivery
23 February 2000
IDEA gets milestone payment from P&G
12 January 2000
Schwarz Pharma boosts CNS pipeline
29 December 1999
Novartis sublicenses HRT patches from R-PR
11 October 1999
Watson buys back Alora from P&G
11 October 1999
Transdermal insulin shows promise
30 September 1999
North Asian markets for OTC analgesics
5 August 1999
J&J developing novel contraceptive patch
22 July 1999
Unimed files NDA for hypogonadism
16 July 1999
Alternative delivery mkt set for fast growth
12 July 1999
Noven plans 2001 filing for ADHD patch
3 June 1999
SB licences Memric to UK biotech Cerebrus
1 June 1999
Galen plans vaginal ring launch within a year
28 May 1999
World's smallest HRT patch launched in USA
13 May 1999
Unimed files NDA for Androgel in USA
6 May 1999
Isis, Elan link up for oral antisense drugs
13 April 1999
Amgen sets aside $100m for abarelix in 1999
18 March 1999
Tackling lipodystrophy after HIV therapy
26 January 1999
New Noven ERT patch
13 January 1999
Elan Completes Ziconotide Phase III In Neuropathic Pain
15 December 1998
Wyeth-Ayerst Submits NDA to US FDA
3 December 1998
Elan's Combi Nicotine Patch A Partial Success
24 November 1998
US FDA Approves Groupe Fournier's Esclim
12 November 1998
Germany's IDEA Signs Deal With P&G
2 November 1998
David Swanson New VP At Alza
29 October 1998
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Alza and Pharmagenesis launch Testoderm
15 October 1998
Aphton Starts Phase I/II Trial Of Gonadimmune
14 October 1998
SB Gets Nicotine Clearance In China
24 September 1998
Bioadhesive Buccal Testosterone HRT
1 September 1998
Cellegy's Glylorin Effective in Follow-Up Indication
19 August 1998
Nortran Tests Local Anesthetic In Phase II
23 July 1998
Stock Commentary Europe
16 July 1998
Noven Files To Market HRT Patch In UK
9 July 1998
Adolor To Investigate ADL 2-1294 In Corneal Pain
30 June 1998
Fournier Makes Swedish Acquisition
15 June 1998
Pharmaceutical Companies Face Up To The Future
15 June 1998
Merck & Co's Propecia "Not Effective In Women"
14 May 1998
Euro CPMP April Plenary Meeting
27 April 1998
J&J 1st Quarter Earnings Rise But Strong $ Hits Sales
15 April 1998
France's Fournier Gets Ready To Blossom
12 March 1998
Cellegy's Glyorin Falls At Phase III
11 March 1998
MacroChem's Topiglan: Phase IIb Data
5 March 1998
Long-Term Efficacy With Merck & Co's Proscar
5 March 1998
$22 Billion World Drug Delivery Market In 1996
4 March 1998
Male Hormone Replacement Can Cut Osteoporosis
19 February 1998
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Negative US patent ruling for Novo Nordisk on Prandin
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- US Supreme Court says patent settlement can "sometimes" be illegal
- Daiichi Sankyo files for Japanese approval of Prasugrel
